Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications

Laura G. Greer, Jeanne S. Sheffield, Vanessa L. Rogers, Scott W. Roberts, Donald D. McIntire, George D. Wendel

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Objective: To review the maternal and neonatal outcomes after antepartum exposure to M2 ion channel inhibitors or oseltamivir to provide some guidance on the risk, if any, of antiviral medication during pregnancy. Methods: This was a retrospective cohort study examining maternal and neonatal outcomes after antepartum exposure to antiviral therapy for influenza. We evaluated maternal characteristics, pregnancy outcomes, and fetal outcomes and compared them with our overall obstetric population. Results: Exposure to antiviral therapies (M2 ion channel inhibitors [n=104] compared with oseltamivir [n=135] compared with the control group [n=82,097]) during pregnancy was not associated with increased rates of preterm birth (7% compared with 10% compared with 6%, P=.190), premature rupture of membranes (23% compared with 16% compared with 22%, P=.154), gestational diabetes (4% compared with 8% compared with 6%, P=.388), or preeclampsia (6% compared with 1% compared with 4%, P=.209). Exposure was not associated with increased duration of hospital stay for mother or neonate. There were no differences in the incidence of minor malformations (19% compared with 15% compared with 22%, P=.101). Liveborn singletons without major malformations did not have differences in fetal weight (3,238±586 g compared with 3,281±642 g compared with 3,336±571 g, P=.186), need for intubation (2% compared with 0.8% compared with 1%, P=.552), intensive care nursery admission (3% compared with 3% compared with 2%, P=.418), or hyperbilirubinemia (12% compared with 9% compared with 8%, P=.282). Liveborn singletons had no grade 3 or 4 intraventricular hemorrhages, seizures, or neonatal deaths. Two preterm neonates exposed to different classes of medications had necrotizing enterocolitis (1.0% compared with 0.8% compared with 0.02%, P<.001). Conclusion: We found no evidence of an association between antepartum antiviral exposure and adverse outcomes.

Original languageEnglish (US)
Pages (from-to)711-716
Number of pages6
JournalObstetrics and Gynecology
Volume115
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Human Influenza
Antiviral Agents
Mothers
Oseltamivir
Ion Channels
Pregnancy
Necrotizing Enterocolitis
Fetal Weight
Hyperbilirubinemia
Gestational Diabetes
Nurseries
Premature Birth
Therapeutics
Critical Care
Pregnancy Outcome
Pre-Eclampsia
Intubation
Obstetrics
Rupture
Length of Stay

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. / Greer, Laura G.; Sheffield, Jeanne S.; Rogers, Vanessa L.; Roberts, Scott W.; McIntire, Donald D.; Wendel, George D.

In: Obstetrics and Gynecology, Vol. 115, No. 4, 04.2010, p. 711-716.

Research output: Contribution to journalArticle

@article{8e820f48055b4b99b1b9857ffdacdf09,
title = "Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications",
abstract = "Objective: To review the maternal and neonatal outcomes after antepartum exposure to M2 ion channel inhibitors or oseltamivir to provide some guidance on the risk, if any, of antiviral medication during pregnancy. Methods: This was a retrospective cohort study examining maternal and neonatal outcomes after antepartum exposure to antiviral therapy for influenza. We evaluated maternal characteristics, pregnancy outcomes, and fetal outcomes and compared them with our overall obstetric population. Results: Exposure to antiviral therapies (M2 ion channel inhibitors [n=104] compared with oseltamivir [n=135] compared with the control group [n=82,097]) during pregnancy was not associated with increased rates of preterm birth (7{\%} compared with 10{\%} compared with 6{\%}, P=.190), premature rupture of membranes (23{\%} compared with 16{\%} compared with 22{\%}, P=.154), gestational diabetes (4{\%} compared with 8{\%} compared with 6{\%}, P=.388), or preeclampsia (6{\%} compared with 1{\%} compared with 4{\%}, P=.209). Exposure was not associated with increased duration of hospital stay for mother or neonate. There were no differences in the incidence of minor malformations (19{\%} compared with 15{\%} compared with 22{\%}, P=.101). Liveborn singletons without major malformations did not have differences in fetal weight (3,238±586 g compared with 3,281±642 g compared with 3,336±571 g, P=.186), need for intubation (2{\%} compared with 0.8{\%} compared with 1{\%}, P=.552), intensive care nursery admission (3{\%} compared with 3{\%} compared with 2{\%}, P=.418), or hyperbilirubinemia (12{\%} compared with 9{\%} compared with 8{\%}, P=.282). Liveborn singletons had no grade 3 or 4 intraventricular hemorrhages, seizures, or neonatal deaths. Two preterm neonates exposed to different classes of medications had necrotizing enterocolitis (1.0{\%} compared with 0.8{\%} compared with 0.02{\%}, P<.001). Conclusion: We found no evidence of an association between antepartum antiviral exposure and adverse outcomes.",
author = "Greer, {Laura G.} and Sheffield, {Jeanne S.} and Rogers, {Vanessa L.} and Roberts, {Scott W.} and McIntire, {Donald D.} and Wendel, {George D.}",
year = "2010",
month = "4",
doi = "10.1097/AOG.0b013e3181d44752",
language = "English (US)",
volume = "115",
pages = "711--716",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications

AU - Greer, Laura G.

AU - Sheffield, Jeanne S.

AU - Rogers, Vanessa L.

AU - Roberts, Scott W.

AU - McIntire, Donald D.

AU - Wendel, George D.

PY - 2010/4

Y1 - 2010/4

N2 - Objective: To review the maternal and neonatal outcomes after antepartum exposure to M2 ion channel inhibitors or oseltamivir to provide some guidance on the risk, if any, of antiviral medication during pregnancy. Methods: This was a retrospective cohort study examining maternal and neonatal outcomes after antepartum exposure to antiviral therapy for influenza. We evaluated maternal characteristics, pregnancy outcomes, and fetal outcomes and compared them with our overall obstetric population. Results: Exposure to antiviral therapies (M2 ion channel inhibitors [n=104] compared with oseltamivir [n=135] compared with the control group [n=82,097]) during pregnancy was not associated with increased rates of preterm birth (7% compared with 10% compared with 6%, P=.190), premature rupture of membranes (23% compared with 16% compared with 22%, P=.154), gestational diabetes (4% compared with 8% compared with 6%, P=.388), or preeclampsia (6% compared with 1% compared with 4%, P=.209). Exposure was not associated with increased duration of hospital stay for mother or neonate. There were no differences in the incidence of minor malformations (19% compared with 15% compared with 22%, P=.101). Liveborn singletons without major malformations did not have differences in fetal weight (3,238±586 g compared with 3,281±642 g compared with 3,336±571 g, P=.186), need for intubation (2% compared with 0.8% compared with 1%, P=.552), intensive care nursery admission (3% compared with 3% compared with 2%, P=.418), or hyperbilirubinemia (12% compared with 9% compared with 8%, P=.282). Liveborn singletons had no grade 3 or 4 intraventricular hemorrhages, seizures, or neonatal deaths. Two preterm neonates exposed to different classes of medications had necrotizing enterocolitis (1.0% compared with 0.8% compared with 0.02%, P<.001). Conclusion: We found no evidence of an association between antepartum antiviral exposure and adverse outcomes.

AB - Objective: To review the maternal and neonatal outcomes after antepartum exposure to M2 ion channel inhibitors or oseltamivir to provide some guidance on the risk, if any, of antiviral medication during pregnancy. Methods: This was a retrospective cohort study examining maternal and neonatal outcomes after antepartum exposure to antiviral therapy for influenza. We evaluated maternal characteristics, pregnancy outcomes, and fetal outcomes and compared them with our overall obstetric population. Results: Exposure to antiviral therapies (M2 ion channel inhibitors [n=104] compared with oseltamivir [n=135] compared with the control group [n=82,097]) during pregnancy was not associated with increased rates of preterm birth (7% compared with 10% compared with 6%, P=.190), premature rupture of membranes (23% compared with 16% compared with 22%, P=.154), gestational diabetes (4% compared with 8% compared with 6%, P=.388), or preeclampsia (6% compared with 1% compared with 4%, P=.209). Exposure was not associated with increased duration of hospital stay for mother or neonate. There were no differences in the incidence of minor malformations (19% compared with 15% compared with 22%, P=.101). Liveborn singletons without major malformations did not have differences in fetal weight (3,238±586 g compared with 3,281±642 g compared with 3,336±571 g, P=.186), need for intubation (2% compared with 0.8% compared with 1%, P=.552), intensive care nursery admission (3% compared with 3% compared with 2%, P=.418), or hyperbilirubinemia (12% compared with 9% compared with 8%, P=.282). Liveborn singletons had no grade 3 or 4 intraventricular hemorrhages, seizures, or neonatal deaths. Two preterm neonates exposed to different classes of medications had necrotizing enterocolitis (1.0% compared with 0.8% compared with 0.02%, P<.001). Conclusion: We found no evidence of an association between antepartum antiviral exposure and adverse outcomes.

UR - http://www.scopus.com/inward/record.url?scp=77949909243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949909243&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3181d44752

DO - 10.1097/AOG.0b013e3181d44752

M3 - Article

C2 - 20308829

AN - SCOPUS:77949909243

VL - 115

SP - 711

EP - 716

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 4

ER -